EcuCri: Complement inhibitors for the therapy of myasthenia gravis in the setting of a myasthenic crisis - a retrospective data analysis

Study Description:

In this research project, we analyze the data of patients whom therapy with complement inhibitor (eculizumab or ravulizumab) was started in an intensive care unit or a monitoring unit due to a myasthenic crisis or a severe worsening of their myasthenia. In addition, we would like to evaluate to what extent the initiation of such treatment influenced the further course of the disease in the ICU. For example, we will look at how soon after the start of this treatment weaning from ventilation or discharge or transfer from the ICU was possible, whether further treatments (e.g., blood washing, so-called plasmapheresis) were necessary, and whether complications (e.g., infections) occurred.
This is a retrospective data evaluation. This means that only data already collected in the past from medical records are collected and analyzed.

Contact: Dr. med. Lea Gerischer

Head of study Prof. Dr. Andreas Meisel

Study coordination Dr. med. Lea Gerischer

Registration: The study is registered in the DRKS DRKS00032104

Duration of data collection: 08/2023- (expected) 05/2024

Project partners: list to follow

Funding: by Alexion Pharma Germany